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Statins reduce cardiovascular mortality and morbidity as well as cardiovascular events in patients 
with a very high risk of cardiovascular disease and also in subjects with a moderate or high risk by 
reducing the levels of low-density lipoprotein cholesterol.
Although statins are considered to be drugs with a very good safety profile, their wide use seems to 
evoke concerns about the compromising adverse effects overpowering proven beneficial ones.
Patients frequently discontinue statin therapy without medical advice due to unfavorable events, 
thereby substantially increasing their risk of cardiovascular events. Statin discontinuation is a great 
problem and appears to be growing.
Complete statin intolerance is relatively rare. Step-by-step approach that includes careful examina-
tion of all possible statin-intolerance-increasing factors would help patients to continue statin therapy 
even if experiencing statin-associated side effects.
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